Article
Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients.
Kidney international - 1 Nov 2011
Derebail Vimal K, Nachman Patrick H, Key Nigel S, Ansede Heather, Falk Ronald J, Rosamond Wayne D, Kshirsagar Abhijit V
Abstract excerpt
African-American patients with end-stage renal disease have historically lower hemoglobin concentrations and higher requirements of erythropoiesis-stimulating agent (ESA). While disparities in health-care access may partially explain these findings, the role of variant hemoglobin, such as sickle trait, has not been investigated. To clarify this, we evaluated 154 African-American patients receiving in-center...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.